Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Tax Provisions: 2009-2025

Historic Tax Provisions for Amicus Therapeutics (FOLD) over the last 12 years, with Sep 2025 value amounting to $17.0 million.

  • Amicus Therapeutics' Tax Provisions rose 25.56% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 47.59%. This contributed to the annual value of $27.4 million for FY2024, which is 1744.23% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Tax Provisions of $17.0 million as of Q3 2025, which was up 223.88% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Tax Provisions peaked at $17.0 million during Q3 2025, and registered a low of -$14.2 million during Q4 2022.
  • Over the past 3 years, Amicus Therapeutics' median Tax Provisions value was $3.6 million (recorded in 2025), while the average stood at $5.0 million.
  • The largest annual percentage gain for Amicus Therapeutics' Tax Provisions in the last 5 years was 2,310.44% (2022), contrasted with its biggest fall of 576.82% (2022).
  • Over the past 5 years, Amicus Therapeutics' Tax Provisions (Quarterly) stood at $3.0 million in 2021, then crashed by 576.82% to -$14.2 million in 2022, then surged by 115.36% to $2.2 million in 2023, then crashed by 411.73% to -$6.8 million in 2024, then rose by 25.56% to $17.0 million in 2025.
  • Its last three reported values are $17.0 million in Q3 2025, $5.2 million for Q2 2025, and $3.6 million during Q1 2025.